Trasylol (Aprotinin) - Summary

TRASYLOL SUMMARY

Trasylol® (aprotinin injection), C₂₈₄ H₄₃₂ N₈₄ O₇₉ S₇, is a natural proteinase inhibitor obtained from bovine lung.

Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery.

See all Trasylol indications & dosage >>

TRASYLOL NEWS HIGHLIGHTS

Published Studies Related to Trasylol (Aprotinin)

Efficacy of a high-dose aprotinin regimen for reducing transfusion requirements and inflammatory responses in adult cardiac surgery. [2008.09]

A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery. [2008.09]

Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass. [2008.09]

The efficacy of aprotinin in arterial switch operations in infants. [2008.09]

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. [2008.05.29]

more >>

Clinical Trials Related to Trasylol (Aprotinin)

Phase I Study of Aprotinin in Advanced Breast Cancer [Terminated]

Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates [Active, not recruiting]

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery [Completed]

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement [Completed]

Aprotinin US Special Access Protocol [Available]

more >>